News about Clinical Trials

Newron Pharmaceuticals Pauses US Enrollment in ENIGMA-TRS 2 Study

Newron Pharmaceuticals pauses enrolment at US sites in ENIGMA-TRS 2 study, while global ENIGMA-TRS 1 trial continues with more than 400 patients enrolled.

Clinical Trials | 02/05/2026 | By News Bureau

Sonire Therapeutics Launches First US Trial of HIFU Therapy for Pancreatic Cancer

Sonire Therapeutics begins US clinical testing of its HIFU platform, aiming to improve outcomes in hard-to-treat pancreatic cancer.

Clinical Trials | 01/05/2026 | By News Bureau

Vensica Medical Secures US FDA Clearance to Advance Needle-Free OAB Therapy to Phase II

Vensica Medical moves forward with clinical trials of its needle-free drug delivery platform aimed at improving access and patient comfort in overactive bladder treatment.

Clinical Trials | 01/05/2026 | By News Bureau

Pfizer's ELREXFIO Boosts Progression-Free Survival in Relapsed Multiple Myeloma

Pfizer’s ELREXFIO meets primary endpoint in MagnetisMM-5, showing significant progression-free survival benefit in relapsed/refractory multiple myeloma, with consistent safety and ongoing evaluation of Overall Survival (OS).

Clinical Trials | 01/05/2026 | By News Bureau

Precision BioSciences Begins Patient Enrollment in Phase 1/2 FUNCTION-DMD Trial

Precision BioSciences activates its first clinical site at Arkansas Children’s Hospital and begins patient enrollment in the phase 1/2 FUNCTION-DMD trial of PBGENE-DMD for Duchenne muscular dystrophy.

Clinical Trials | 30/04/2026 | By News Bureau

Argo Biopharma Doses First Patient in Phase 1 Trial of siRNA Drug BW-50218

Argo Biopharma doses first patient in Phase 1 trial of BW-50218, an siRNA therapeutic from its RADS platform designed for potent, durable gene silencing with targeted hepatic delivery and improved safety.

Clinical Trials | 29/04/2026 | By News Bureau

Soligenix Reports Phase 3 FLASH2 Interim Results for HyBryte in Cutaneous T-Cell Lymphoma

Soligenix reports Phase 3 FLASH2 interim results for HyBryte in Cutaneous T-Cell Lymphoma, with the study recommended for early termination due to futility.

Clinical Trials | 29/04/2026 | By News Bureau

Cellenkos Inc. Wins US FDA Clearance for Phase 2 Trial of CK0801 in Aplastic Anemia

Cellenkos Inc. receives US Food and Drug Administration (FDA) clearance to initiate a Phase 2 multicentre trial of CK0801, evaluating safety and efficacy of cord blood-derived Tregs in transfusion-dependent aplastic anemia patients.

Clinical Trials | 27/04/2026 | By News Bureau

Thryv Therapeutics Advances THRV-1268 Programme with Phase II/III Trial and FDA Fast Track Status

Thryv Therapeutics initiates Phase II/III clinical testing and secures FDA Fast Track status for THRV-1268, advancing a potential first-in-class therapy for Long QT Syndrome.

Clinical Trials | 27/04/2026 | By News Bureau

Ascletis Pharma Completes US Phase 2 Enrollment for ASC30 GLP-1R Agonist

Ascletis Pharma completes US Phase 2 enrollment for ASC30, an oral GLP-1R agonist for diabetes. The 13-week study evaluates safety, efficacy, and tolerability in 100 patients, with topline results expected in Q3 2026.

Clinical Trials | 27/04/2026 | By News Bureau